Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level

Cancer

Volumn 109, Issue 2, 2007, Pages 198-204

  Leibovici, Dan ^a   Spiess, Philippe E ^a   Agarwal, Piyush K ^a   Tu, Shi Ming ^a   Pettaway, Curtis A ^a   Hitzhusen, Kate ^a   Millikan, Randall E ^a   Pisters, Louis L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Ductal; Progression; Prostate cancer; Prostate specific antigen; Small cell

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; BONE METASTASIS; BRAIN METASTASIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; GLEASON SCORE; HISTOLOGY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SMALL CELL CARCINOMA; TREATMENT INDICATION;

AGED; BONE NEOPLASMS; BRAIN NEOPLASMS; DISEASE PROGRESSION; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 33846189743     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22372     Document Type: Review

References (26)

1. Schaklen JA. Molecular and cellular prostate biology: origin of prostate-specific antigen expression and implications for benign prostatic hyperplasia. BJU Int. 2004;93:5-9.
2. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597.
3. Dotan ZA, Bianco FJ Jr, Rabbani F, et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol. 2005;23:1962-1968.
4. Stein A, deKernion JB, Dorey F. Prostatic specific antigen related to clinical status 1 to 14 years after radical retropubic prostatectomy. Br J Urol. 1991;67:626-631.
5. Pound CR, Christens-Barry OW, Gurganus RT, et al. Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy. J Urol. 1999;162:1337-1340.
6. Chow E, McLean M, Patterson B, et al. Progression of prostate cancer despite undetectable serum prostate specific antigen. Can J Urol. 1998;5:620-622.
7. Nishio R, Furuya Y, Nagakawa O, et al. Metastatic prostate cancer with normal level of serum prostate-specific antigen. Int Urol Nephrol. 2003;35:189-192.
8. Trotz C. Prostate cancer with a normal PSA: small cell carcinoma of the prostate-a rare entity. J Am Board Fam Pract. 2003;16:343-344.
9. Vijayakumar V, Vijayakumar S, Quadri SF, et al. Can prostate-specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer? Am J Clin Oncol. 1994;17:432-436.
10. Rudoni M, Antonini G, Favro M, et al. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer. Eur J Nucl Med. 1995;22:207-211.
11. Levran Z, Gonzalez JA, Diokno AC, et al. Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer? Br J Urol. 1995;75:778-781.
12. Yap BK, Choo R, Deboer G, et al. Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade prostate cancer managed with watchful observation alone? BJU Int. 2003;91:613-617.
13. Gomez P, Manoharan M, Kim SS, et al. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int. 2004; 94:299-302.
14. Leibman BD, Dillioglugil O, Wheeler TM, et al. Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. Cancer. 1995;76:2530-2534.
15. Oefelein MG, Smith N, Carter M, et al. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J Urol. 1995;154:2128-2131.
16. Hubler J, Sukosd F, Czipri M. Tibia metastasis without prostate specific antigen (PSA) increase following radical vesiculo-prostatectomy. Int Urol Nephrol. 2000;32:281-284.
17. Yamamoto S, Ito T, Akiyama A, et al. M1 prostate cancer with a serum level of prostate-specific antigen less than 10 ng/mL. Int J Urol. 2001;8:374-379.
18. Kane CJ, Amling CL, Johnstone PA, et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology. 2003;61:607-611.
19. Sella A, Konichezky M, Flex D, et al. Low PSA metastatic androgen-independent prostate cancer. Eur Urol. 2000;38:250-254.
20. Schwartz LH, LaTrenta LR, Bonaccio E, et al. Small cell and anaplastic prostate cancer: correlation between CT findings and prostate-specific antigen level. Radiology. 1998;208:735-738.
21. Lilja H, Oldbring J, Rannevik G, et al. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest. 1987;80:281-285.
22. Magklara A, Scorilas A, Stephan C, et al. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology. 2000;56:527-532.
23. Helpap B, Kollermann J. Undifferentiated carcinoma of the prostate with small cell features: immunohistochemical subtyping and reflections on histogenesis. Virchows Arch. 1999;434:385-391.
24. Tu SM, Lin SW, Logothetis CJ. Stem-cell origin of metastasis and heterogeneity in solid tumors. Lancet Oncol. 2002;3: 508-513.
25. Valle J, von Boguslawsky K, Stenborg M, et al. Progression from adenocarcinoma to small cell carcinoma of the prostate with normalization of prostate-specific antigen (PSA) levels. Scand J Urol Nephrol. 1996;30:509-512.
26. Tu SM, Reyes A, April M, et al. Prostate carcinoma with testicular or penile metastases clinical, pathologic, and immunohistochemical features. Cancer. 2002;94:2610-2617.